With precision medicine an increasingly hot topic in health care, MedImpact is betting that a newly launched program — which reviews every drug prescribed to patients against their genetic profile — will simultaneously give the PBM a competitive edge and improve care. Experts tell AIS Health that such a program could usher in changes to the PBM industry if it proves successful and sparks a larger trend.
- Datapoint, Medicare and Medicaid
- Abstract, Health Plans
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits